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Building a Statistical Model for Predicting Cancer Genes
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Abstract
More than 400 cancer genes have been identified in the human genome. The list is not yet complete. Statistical models
predicting cancer genes may help with identification of novel cancer gene candidates. We used known prostate cancer
(PCa) genes (identified through KnowledgeNet) as a training set to build a binary logistic regression model identifying PCa
genes. Internal and external validation of the model was conducted using a validation set (also from KnowledgeNet),
permutations, and external data on genes with recurrent prostate tumor mutations. We evaluated a set of 33 gene
characteristics as predictors. Sixteen of the original 33 predictors were significant in the model. We found that a typical PCa
gene is a prostate-specific transcription factor, kinase, or phosphatase with high interindividual variance of the expression
level in adjacent normal prostate tissue and differential expression between normal prostate tissue and primary tumor. PCa
genes are likely to have an antiapoptotic effect and to play a role in cell proliferation, angiogenesis, and cell adhesion. Their
proteins are likely to be ubiquitinated or sumoylated but not acetylated. A number of novel PCa candidates have been
proposed. Functional annotations of novel candidates identified antiapoptosis, regulation of cell proliferation, positive
regulation of kinase activity, positive regulation of transferase activity, angiogenesis, positive regulation of cell division, and
cell adhesion as top functions. We provide the list of the top 200 predicted PCa genes, which can be used as candidates for
experimental validation. The model may be modified to predict genes for other cancer sites.
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secondary (i.e., related) terms. As a result, each gene receives
a confidence score (CS): the higher the CS, the stronger the
association of the gene with a specified phenotype; in our case,
PCa. We identified a total of 707 genes with CSs ranging from
2.663 to 0.001 (Table S1) and used the top 100 genes as ‘‘known
PCa genes.’’ The other 607 genes from the list were considered
‘‘putative PCa genes.’’ The remaining 14,641 genes with
a CS,0.001 were considered ‘‘non-PCa genes.’’ We excluded
the 607 putative PCa genes to create a well-defined binary
outcome for our analysis.
Because our initial search term to identify PCa genes was
‘‘prostate cancer,’’ the algorithm searches the genes associated
with any aspects of prostate carcinogenesis, including initiation,
progression, recurrence, and survival. In other words, we used
a broad definition of PCa genes. Of course, a search can be more
specific, e.g., ‘‘prostate cancer recurrence,’’ and this is expected to
produce a training set that will be different from the list we used.

Introduction
A census of human cancer genes conducted by Futreal et al. [1]
and updated by Santarious et al. [2] to identify 400 cancer-related
genes. It is obvious that this list of cancer-related genes is not
complete: a PubMed search of the literature conducted in June
2011 using the term ‘‘novel cancer gene’’ in the title identified
more than 100 papers published in 2011 (data not shown).
Development of a predictive model for cancer genes could
accelerate their identification. In this study, we developed
a statistical model for the prediction of prostate cancer (PCa)
genes. Our study was motivated by the following: i) a number of
PCa-related genes with strong experimental evidence have been
identified, ii) many genes in the human genome are extensively
annotated, and iii) genome-wide profiling of gene-expression data
is available [3,4]. In this study, we identified traits that are
characteristic of known PCa genes and used them to predict novel
PCa genes.

Model and Variables
Materials and Methods

A binary logistic regression (BLR) model was used to
discriminate between the ‘‘known PCa’’ and the ‘‘non-PCa’’
genes. Each gene was described by 33 variables (Table 1). The
variables were selected on the basis of evidence published by us
and others that the individual variables are associated with PCa
[6–11]. A detailed description of the variables can be found in the

Known PCa Genes
We used the KnowledgeNet (KN; a literature-mining algorithm)
approach to identify PCa genes [5]. The KN algorithm searches
for an association between the gene and both primary and
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reduce the risk of experimental follow-up of false positives, which
can be costly.
In total, we used 15,348 genes. Gene expression data were
a limiting factor of inclusion of each gene in the analysis. We used
the publicly available datasets GSE6919 [12,13] and GSE21034
[13] from the Gene Expression Omnibus (GEO) [3,4] and used
AmiGO2 [14] to identify the genes associated with specific biologic
function, cellular location, and posttranslational modifications.
The number of human orthologs reported in the HomoloGene
database (http://www.ncbi.nlm.nih.gov/HomoloGene) was used
as the evolutionary conservation index [15,16].

Information S1. We subclassified the variables into two categories:
prostate-tissue specific and nonspecific. Tissue-specific variables
included gene expression data in normal and tumorous prostate
tissues. Non–tissue-specific variables were those that can be
applied to any type of tissue, e.g., ‘‘growth factor,’’ ‘‘phosphorylated’’ variables.
Because our regression model was naturally unbalanced, with
too many ‘‘non-PCa’’ genes and too few PCa genes, we could not
use a 0.5 threshold to decide whether the gene was a PCa or ‘‘nonPCa’’ gene. The classification threshold (0.05) was chosen to
ensure that at least 95% of non-PCa genes were predicted
correctly, and because it reflects the proportion of genes that were
identified as prostate cancer (707) related to the total number of
genes studied in the training phase (14,641). This relatively high
rate of correct classification of ‘‘non-PCa’’ genes was selected to

Validation of the Model
To validate the model, we first randomly subclassified the 200
genes with the highest CS into discovery and validation sets. Next
we built the BLR model by using only the discovery set and used it

Table 1. Variables used to build a binary logistic model to discriminate known PCa genes.

Type of variable

Variable

Source of the data

Specific

Three-level meta-analysis

Ref. [10]

Nonspecific

Acetylated

GO*

Nonspecific

Angiogenesis

GO

Nonspecific

Antiapoptotic

GO

Nonspecific

Cell adhesion

GO

Nonspecific

Cell proliferation

GO

Nonspecific

Chromatin remodeling

GO

Specific

Difference in expression –LOG(P)

Refs. [12,13]

Nonspecific

DNA repair

GO

Nonspecific

DNA replication

GO

Nonspecific

Evolutionary conservation index

HomoloGene{

Nonspecific

Expression level in normal prostate

Ref. [25]

Nonspecific

Extracellular space

GO

Nonspecific

Growth factors

GO

Nonspecific

Housekeeping gene

Ref. [26]

Nonspecific

Kinases

GO

Specific

Mean expression in adjacent tissue

Refs. [12,13]

Specific

Mean expression in tumor tissue

Refs. [12,13]

Specific

Meta-analysis of the gene expression

Ref. [8]

Nonspecific

Methylated

GO

Nonspecific

Phosphatases

GO

Nonspecific

Phosphorylated

GO

Nonspecific

Plasma membrane

GO

Specific

Prostate-specific expression (enrichment score)

Ref. [25]

Nonspecific

Secreted

GO

Nonspecific

Signal transduction

GO

Nonspecific

Sumoylated

GO

Nonspecific

Transcription

GO

Nonspecific

Transcription factors

GO

Nonspecific

Translation

GO

Nonspecific

Ubiquitinated

GO

Specific

Variance in adjacent tissue

Refs. [12,13]

Specific

Variance in tumor tissue

Refs. [12,13]

*GO, Gene Ontology database [27,28].
{
HomoloGene Database: http://www.ncbi.nlm.nih.gov/homologene.
doi:10.1371/journal.pone.0049175.t001
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to predict PCa genes in the validation set. For additional internal
validation, we built the BLR model by using the top 100 genes,
excluding the putative PCa genes, and then applied the model to
compute the probability for the putative PCa genes. We expected
that the probability of being classified as a PCa gene would be
higher for the putative genes than it would be for the non-PCa
genes. Further, we performed permutation testing by randomly
assigning PCa gene status. We built a BLR model for those
‘‘mock’’ PCa genes by using the same set of variables we used for
the ‘‘real’’ PCa genes (i.e., those identified with KN). We
performed this procedure 100 times and estimated the percentage
of the correctly predicted PCa genes.
For external validation, we checked to see whether the modelderived probability of a gene’s being PCa related was higher for
genes for which recurrent somatic mutations in prostate tumor
samples are reported in the Catalogue of Somatic Mutations in
Cancer (COSMIC) database [17,18]. We also used the genes
identified as having recurrent somatic mutations in the recently
published study results of whole-exome sequencing of prostate
tumor samples [19]. Note, however, that we did not use somatic
mutation data to build our model.

Table 2. Variables significant in the multivariable binary
logistic regression model with putative PCa genes excluded.

Is the Predicting Model Prostate Specific?
To answer this question, we identified the top 100 breast and
top 100 lung cancer genes (Table S2) by using the same KN
algorithm we used to identify the PCa genes. Then we compared
the percentages of correctly predicted breast and lung cancer
genes with the percentage of correctly predicted PCa genes.
We built BLR models on the basis of only specific (‘‘specific
model’’) and nonspecific (‘‘nonspecific model’’) predictors. Then
we estimated the percentages of correctly predicted non-PCa and
PCa genes for each model. Statistical analysis was conducted using
SPSS version 15.0.

B*

SE

x2

Prostate-specific expression
(enrichment score)

0.313

0.039

66.116 1

,0.001
,0.001

df

p Value

Kinases

1.929

0.333

33.647 1

Variance in adjacent tissue

0.68

0.131

27.097 1

,0.001

Phosphatases

2.486

0.483

26.469 1

,0.001

Growth factors

1.818

0.453

16.132 1

,0.001

Meta-analysis of the
gene expression

0.143

0.037

15.226 1

,0.001

Transcription factors

1.201

0.326

13.562 1

,0.001

Antiapoptotic

1.497

0.415

13.043 1

,0.001

Extracellular space

0.91

0.303

9.05

1

0.003

Signal transduction

0.781

0.272

8.269

1

0.004

Cell proliferation

1.131

0.396

8.154

1

0.004

Ubiquitinated

0.574

0.244

5.542

1

0.019

Angiogenesis

1.062

0.461

5.32

1

0.021

Acetylated

20.577 0.251

5.276

1

0.022

Cell adhesion

0.804

0.386

4.342

1

0.037

Sumoylated

0.937

0.466

4.043

1

0.044

*B, regression coefficient; SE, standard error.
doi:10.1371/journal.pone.0049175.t002

known, putative, and non-PCa genes. The proportions of the
genes predicted to be PCa related were 0.05260.002 for the nonPCa genes, 0.22460.017 for the putative PCa genes, and
0.54760.049 for the known PCa genes. As noted earlier, we also
built a model that included the putative PCa genes as non-PCa
genes. Overall, the prediction accuracy was lower with this model,
with the proportions of the genes predicted to be PCa associated
being 0.03760.002 for the non-PCa genes, 0.21760.016 for the
putative PCa genes, and 0.45560.049 for the known PCa genes.

Results
Predicted PCa Genes
Among the 33 variables, 22 were significant in the univariable
analysis (Table S3), whereas in the multivariable stepwise-forward
(likelihood ratio) BLR model, 16 variables were significant
(Table 2). The model correctly predicted 96% of the non-PCa
genes and 55% of the PCa genes and was more accurate than the
model built on the data that included the putative PCa genes as
non-PCa genes, in which 96% of non-PCa genes and 46% of PCa
genes were predicted correctly.
Table S4 lists the top 200 predicted PCa genes and indicates
whether they were known, putative, or novel predicted genes.
Ranking the genes according to the model-derived probabilities
reshaped the original CS-based list: AR (androgen receptor) was
ranked seventh, not first, as on the original list, and KLK3
(prostate-specific antigen [PSA]) was fourth, although it was
second on the original list. Overall, the correlation between the CS
and the model-derived probability of being PCa related was 0.32,
df = 200; p = 2610–6. Table S5 shows individual variables
contributing to the probability that the gene is associated with
PCa.

Is the Prediction PCa Specific?
To find out whether our predictive model is PCa specific, we
identified the top 100 breast and lung cancer genes using the KNbased approach (Table S2). Overall, the proportion of the
correctly predicted cancer genes was higher for prostate
(0.5560.03) than for breast (0.3760.02) and lung cancers
(0.3160.02). For the model built based on nonspecific predictors
only, accuracy was better for the PCa genes (0.5560.02) than it
was for the breast (0.2460.02) and lung cancer (0.2160.02) genes.
And for the model based on specific predictors, the predicting
efficiency also was higher for prostate (0.3060.02) than it was for
breast (0.0860.01) and lung cancer (0.0860.01) genes.

Discovery and Validation Sets
For internal validation, we randomly assigned the top 200 PCarelated genes to discovery and validation sets so there were 100
genes in each group. We then built the BLR model on the basis of
the discovery set and used it to predict PCa genes from the
validation set. The discovery model correctly predicted 95% of the
non-PCa genes and 4365% of the PCa genes; it predicted similar
proportions in the validation set: 96% of the non-PCa genes and
3865% of the PCa genes. We performed this procedure 100
times.

Putative PCa Genes have a Higher Probability of being
Classified as PCa Related
Putative PCa genes are expected to have a higher probability of
being PCa related than non-PCa genes have. We used our model
based on the data without the putative genes to estimate the
probability that a putative gene is PCa related, comparing the
proportions of the genes predicted to be PCa related between the
PLOS ONE | www.plosone.org
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in adjacent normal prostate tissue, or ubiquitination) are not that
apparent. Because several different factors are involved in
nominating a gene to be prostate cancer related, different genes
show effects from different predictors. The predictors are indicated
in Table S5.
Our model also allows ranking of the genes that are, according
to the model-generated evidence, PCa related and therefore
predictive of novel PCa genes. A brief description of the top ten
novel predicted PCa genes follows.
UPK3A–uroplakin 3A; a member of the uroplakin family,
a group of transmembrane proteins that form complexes on the
apical surface of the bladder epithelium. Mutations in UPK3A are
associated with renal adysplasia [20].
KITLG–encodes the ligand of the tyrosine-kinase receptor. The
gene is believed to play a role in cell migration [21].
NPY–widely expressed in the central nervous system and
influences many physiologic processes, including cortical excitability, stress response, food intake, circadian rhythms, and
cardiovascular function.
GHR–a member of the type I cytokine receptor family.
SCGB1A–a member of the secretoglobin family of small secreted
proteins. The encoded protein has been implicated in numerous
functions, including anti-inflammation, inhibition of phospholipase A2, and sequestration of hydrophobic ligands.
NR3C1–encodes the glucocorticoid receptor, which can function
as both a transcription factor and a regulator of other transcription
factors.
JUP–encodes a protein that is a structural element of
submembranous plaques of desmosomes. It forms complexes with
cadherins.
NPM1–encodes a phosphoprotein that moves between the
nucleus and the cytoplasm. The gene product is thought to be
involved in several processes, including regulation of the ARF/p53
pathway.
CD177–NB1, a glycosyl-phosphatidylinositol–linked N-glycosylated cell-surface glycoprotein, was first described in a case of
neonatal alloimmune neutropenia [22].
FAM55D–chromosome 11 open reading frame 33. Little is
known about this gene, but it is downregulated in prostate tumor.
We conducted functional annotation of novel PCa genes by
using all 15,348 genes as a background to account for possible
selection bias. For the functional annotation, we used the Database
for Annotation, Visualization, and Integrated Discovery (DAVID)
[23]. The top biologic functions associated with the novel PCa
genes were antiapoptosis, regulation of cell proliferation, positive
regulation of kinase activity, positive regulation of transferase
activity, angiogenesis, positive regulation of cell division, cell
adhesion, MAPKKK cascade, bone development, and regulation
of cellular localization. (More detailed information can be found in
the Supporting Information.) There is considerable overlap
between the description of the known and novel predicted PCa
genes’ functions: antiapoptosis, regulation of cell proliferation,
positive regulation of kinase activity, positive regulation of
transferase activity, and MAPKKK cascade are present on both
lists. The only unique function associated with the predicted novel
PCa genes was bone development in ten genes: GHR, AMELX,
TRAF6, FGF9, SMAD1, CTGF, IGF2, AMBN, FGF18, and PTN.
The results of the internal validation demonstrated that PCarelated genes are not a random collection of genes but rather share
a combination of several traits. They also demonstrate that we are
unlikely to overfit the model. External validation demonstrated
that the model-generated probability of being a PCa gene is the
most significant predictor of the PCa candidates identified through
the analysis of recurrent somatic mutations. On the other hand,

Permutations
We randomly assigned PCa status to 100 genes from the 15,348
genes in the original table and built a prediction model for those
‘‘mock’’ genes using the same 33 variables (Table 1). The
procedure was performed 100 times. There were an average of
0–2 significant variables in the mock gene model, and those
variables varied from model to model. On average, 0.760.2%
mock PCa genes were predicted correctly, which is significantly
(p,,10–6) lower than the percentage of the correctly predicted
‘‘true’’ PCa genes (5565%).

External Validation
For external validation, we used the results of the recently
published report on recurrent somatic mutations in prostate
tumors [19]. That study identified 20 genes–BDH1, DKK1, DLK2,
FSIP2, GLI1, IKZF4, KDM4B, MGAT4B, NMI, NRCAM,
PCDH11X, PDZRN3, PLA2G16, RAB32, SDF4, SF3A1, TBX20,
TFG, TP53, and ZNF473–that have recurrent somatic mutations.
Seventeen of those genes (all except BDH1, FSIP2, and PLAG16)
were on our original list of 15,348 genes. We found that the
model-generated probability of being a PCa gene was more than
ten times greater for the genes with recurrent somatic mutations
than it was for all the other genes: 0.08260.041 vs. 0.00760.001;
df = 15,348, t = 5.4, p,10–6 (Figure 1). The other significant
predictors were transcription factors, the CS used to rank the PCa
genes from literature mining, cell proliferation, phosphatases,
growth factors, and angiogenesis. We obtained similar results for
the genes with the reported PCa somatic mutations from the
COSMIC database [18]. The model-derived probability of being
a PCa gene was the most significant predictor of genes with
recurrent somatic mutations in prostate tumors. Other significant
predictors included CS, kinases, antiapoptotic, cell proliferation,
acetylated, plasma membrane, and angiogenesis.

Specific vs. Nonspecific Predictors
We constructed a model based on only specific (eight variables)
and only nonspecific (25 variables) predictors. In the nonspecific
model, 11 variables were significant (in decreasing order of
statistical significance): kinases, phosphatases, extracellular space,
transcription factors, antiapoptotic, signal transduction, growth
factors, cell proliferation, sumoylated, cell adhesion, and angiogenesis. The nonspecific model correctly predicted 95% of nonPCa and 40% of PCa genes; that based on specific variables
correctly predicted 95.5% of non-PCa and 30.2% of PCa genes.
There were four significant predictors in that model (in decreasing
order of statistical significance): prostate-specific expression
(enrichment score), variance in adjacent tissue, meta-analysis of
the gene expression, and three-level meta-analysis.

Discussion
We have identified a combination of traits that is characteristic
of PCa genes: a typical PCa gene is a prostate-specific
transcription factor, kinase, or phosphatase with high interindividual variance in adjacent normal prostate tissue and is expressed
differently (upregulated or downregulated) in normal prostate
tissue and primary tumor. PCa genes are likely to have an
antiapoptotic effect and play a role in cell proliferation,
angiogenesis, and cell adhesion. Their products are likely to be
ubiquitinated or sumoylated but not acetylated. They are likely to
be involved in signal transduction and being a component of
extracellular space. Some of the identified characteristics of PCa
genes (e.g., cell proliferation or angiogenesis) are obvious, whereas
others (e.g., tissue specificity, higher variance of the gene expression
PLOS ONE | www.plosone.org
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Figure 1. Variables that discriminate genes with recurrent somatic mutations in prostate tumors from all other genes. Vertical line
represents a threshold for statistical significance.
doi:10.1371/journal.pone.0049175.g001

following secondary terms: prostate cancer cells, prostate cancer
risk, Gleason, androgen-independent, prostatic neoplasms, Gleason score, prostatectomy, metastatic prostate, human prostate
cancer, radical prostatectomy, androgen-independent prostate,
advanced prostate, prostate-specific antigen, primary prostate,
benign prostate, prostate tumors, prostate-specific, prostate
carcinogenesis, and benign prostatic. Although in its current form
the model is designed to predict broadly defined PCa genes, it can
be adjusted to be more specific; for example, to predict PCaprogression genes. The crucial element here is to define a reliable
training set for PCa genes associated with cancer progression.
The BLR model is one of many available classification
algorithms. To see whether other classification methods could
produce similar results, we also analyzed our data by using linear
discriminant analysis (LDA) and support vector machines (SVM).
We found that LDA and BLR have rather similar classification
efficacies: 51% and 55% correctly classified PCa genes with 95%
and 96% of the correctly classified non-PCa genes, with essentially
the same set of significant predictors in the model. Validation was
also slightly better for the BLR model, with 18% of putative PCa
genes predicted to be PCa genes, compared with 22% for LDA
model. Compared with the BLR, the SVM was more efficient in
the discovery set, correctly predicting 84% of the known PCa
genes and 95% of the non-PCa genes; however, in the validation,

the presence of somatic mutations in tumor samples may be one of
the factors that elevate the CS and consequently contribute to the
higher chance of being classified as a known PCa gene. Indeed, the
CS was the third most significant predictor of the genes with
recurrent somatic mutations. However, it was lower than the t
statistic for the model-generated probability of being a PCa gene:
5.5 vs. 3.4. The proportion of the genes with COSMIC somatic
mutations was higher among the putative PCa genes: x2 = 22.8,
df = 1, p,0.0001. The proportion was borderline higher for the
predicted novel PCa genes: x2 = 3.8, df = 1, p = 0.05. We also
found that the average model-derived probability of the published
112 genes with a signature of positive selection [24] was higher
than that of an average gene in the human genome: Student’s t
test = 2.0, df = 30,495, p = 0.04. The overlap is modest but
significant, especially if we take into account that the published
list of the cancer genes was generated for any type of cancer, while
in our study we focused on PCa only.
We demonstrated that both specific and nonspecific predictors
are important: models based on only specific or only nonspecific
predictors are less efficient than the model built on combination of
the traits. The specific predictor–based model is more prostate
specific than is the model based on nonspecific predictors.
Obviously the structure of the predicting model depends heavily
on the training set. We used a broad definition of PCa with the

PLOS ONE | www.plosone.org
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The top 100 breast cancer and 100 lung cancer genes
identified by using the KnowledgeNet approach.
(DOCX)

it correctly predicted only 34% of PCa genes, whereas the BLR
model correctly predicted 46% of PCa genes in discovery and 44%
in validation set. Because of that better validation efficiency, we
focused on BLR model.
The next logical step would be experimental validation of the
novel PCa candidates identified by the model. We think that one
of the best ways to do that would be with a high-throughput
screening platform. For example, one can use high-throughput
RNAi screening of PCa cell lines. After silencing of a candidate
gene by RNAi, one can estimate the effect of the gene on cell
proliferation, migration, and apoptosis. Genes with a strong effect
on these cancer-associated phenotypes can be further analyzed in
human tissue to confirm their role in prostate tumorigenesis.
In conclusion, we have developed a bioinformatics-based BLR
model for prediction of the genes associated with PCa. The model
allows ranking human genes according to their probability of
being PCa associated. We identified a number of novel PCa
candidates with high probabilities of being PCa related, and those
candidates may merit further experimental validation. The
approach we used can also be applied to other types of genes
and other types of cancer; we are currently working on the model
for prediction of lung cancer genes.

Information S1 Description of the Variables Used to Build the
Prediction Model. Variables Are Listed in the Order in Which
They Are Presented in Table 1.
(DOCX)

Supporting Information

Author Contributions

The 707 genes with CS ranging from 2.663 to 0.001;
we used the top 100 of these genes as ‘‘known PCa genes.’’
(XLSX)

Conceived and designed the experiments: IG CL CA OG. Analyzed the
data: CA. Wrote the paper: IG OG. Participated in the bioinformatics and
statistical analysis: SF. Read and approved the final manuscript: IG CL SF
OG CA.

Table S2

Univariable analysis identified 22 of the original 33
original variables as significant predictors of PCa genes.
(DOCX)

Table S3

Table S4 Ranking of the top 200 genes by model-generated

probability of being PCa related. P, putative PCa gene; K, known
PCa gene; NP, novel predicted PCa gene.
(DOCX)
Table S5 Individual contributing variables in novel predicted
PCa genes. Highlighted variables contribute to a high probability
for a gene to be PCa associated. For binary variables, positive
contributors have the value of 1; for continuous variables,
predictors have a value higher than m+s, where m is a mean
and s is a standard deviation.
(XLS)

Table S1
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